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Abstract
The aim of the present systematic review was to evaluate the available evidence on laboratory diagnosis of CDI and to formulate
recommendations to optimize CDI testing. In comparison with cell culture cytotoxicity assay (CCA) and toxigenic culture (TC) of
stools, we analyzed the test characteristics of 13 commercial available enzyme immunoasssays (EIA) detecting toxins A and/or B, 4 EIAs
detecting Clostridium difﬁcile glutamate dehydrogenase (GDH), and a real-time PCR for C. difﬁcile toxin B gene. In comparison with
CCA and TCA and assuming a prevalence of CDI of 5%, PPV and NPV varied between 0.28–0.77, 0.12–0.65 and 0.98–1.00, 0.97–1.00,
respectively. Only if the tests were performed in a population with a CDI prevalence of 50 percent, would PPVs be acceptable (ranging
from 0.71 to 1.00).To overcome the problem of a low PPV, we propose a two step approach, with a second test or a reference
method in case of a positive ﬁrst test. Further reducing the number of false negative results would require either retesting of all sub-
jects with a negative ﬁrst test, or re-testing all subjects with a negative second test, after an initially positive test. This approach resulted
in non-signiﬁcant improvements, and emphasizes the need for better diagnostic tests. Further studies to validate the applicability of
two-step testing, including assessment of clinical features, are required.
Keywords: Clostridium difﬁcile, systematic review, diagnostics, recommendations, review
Clin Microbiol Infect 2009; 15: 1053–1066
Corresponding author and reprint requests: E. J. Kuijper,
Department of Medical Microbiology, Leiden University Medical
Center, Leiden, the Netherlands
E-mail: e.j.kuijper@lumc.nl
Introduction
Clostridium difﬁcile is the primary cause of nosocomial diar-
rhoea in industrialized countries. Only toxigenic strains cause
disease, due to the production of toxins A and/or B. The inci-
dence and severity of C. difﬁcile infections (CDI) have been
increasing in recent years [1]. Therefore, the diagnosis of
CDI requires renewed attention, as rapid and accurate diag-
nosis of CDI is not only essential to individual patient man-
agement but also to prevention of nosocomial transmission.
The diagnosis of CDI is usually based on the clinical his-
tory in combination with laboratory tests. Various laboratory
tests are currently available for the detection of C. difﬁcile or
its toxins [2]. The diagnostic tests for C. difﬁcile can be
divided into tests for (i) C. difﬁcile products (glutamate dehy-
drogenase (GDH), aromatic fatty acids, toxins A and/or B),
(ii) culture methods for the detection of toxin-producing
C. difﬁcile (toxigenic culture), and (iii) tests for C. difﬁcile
genes (PCRs for 16S RNA, toxin genes, genes for GDH).
The cell culture cytotoxicity assay (CCA) [3] is still regarded
as the reference standard for the detection of C. difﬁcile tox-
ins. Culture followed by in vitro toxin detection of the iso-
lated strains has been adopted by some investigators as a
more sensitive reference standard than CCA [4], though the
clinical relevance of this so-called toxigenic culture (TC) is
not entirely clear. As the above-mentioned reference stan-
dard methods are time-consuming and require speciﬁc
laboratory facilities and technical expertise, many laborato-
ries have replaced these methods by enzyme immunoassays
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[5]. These are rapid and easy-to-perform assays designed to
detect C. difﬁcile toxins or the enzyme glutamate dehydroge-
nase, which is produced by both toxigenic and non-toxigenic
C. difﬁcile strains. Another new development is the applica-
tion of real-time PCR to detect the toxin genes of C. difﬁcile
directly from stools [6–10].
Though these rapid and easy tests can be attractive alter-
natives to the time-consuming reference standards, they have
been reported to have limited sensitivity and/or speciﬁcity.
This has given rise to many different testing protocols,
including multiple sample submission [11] or multiple testing
of samples by different methods [12–16]. Therefore, we con-
ducted a systematic review to evaluate the diagnostic perfor-
mance of these tests for CDI. In order to provide a
reasonable approach to the diagnosis of CDI, results from
this systematic review were used to formulate recommenda-
tions for CDI testing in clinical practice.
Objective
The main aim of the present systematic review was to evalu-
ate the available evidence concerning laboratory diagnosis of
CDI and to formulate recommendations to optimize CDI
testing in patients suspected of CDI.
Material and Methods
Commonly applied laboratory tests
Cell culture cytotoxicity assay (CCA) and toxigenic culture
(TC) are regarded as reference standard methods for the
diagnosis of CDI. For CCA, stool ﬁltrates are inoculated
onto a monolayer of a cell culture which is then observed
for a toxin B induced cytopathic effect (rounding of the cells)
after 24 and 48 h. Many cell lines can be used for this CCA,
including Vero cells, HeLA cells, human foreskin ﬁbroblasts
and Hep-2 cells. To determine the speciﬁcity of the cyto-
pathic effect, neutralization with an antiserum (C. sordelli anti-
toxin or C. difﬁcile antitoxin) is executed. Toxigenic culture
consists of culture on selective media followed by in vitro
toxin detection (by EIA, CCA or PCR) to determine the
toxigenicity of the isolated strain. Culture of C. difﬁcile is per-
formed on selective media; cycloserine cefoxitin fructose
agar (CCFA) is used in most laboratories [17]. Pretreatment
with alcohol shock is another alternative to decrease the
normal feces ﬂora and to prevent overgrowth [18]. Stools
are incubated in an anaerobic atmosphere for at least 48 h.
Enzyme immunoasssays (EIAs) available for detection of
C. difﬁcile or its toxins include EIAs detecting GDH, EIAs
detecting toxin A only, and EIAs detecting both toxins A and
B. A panel that includes both an EIA detecting toxin A and
an EIA detecting GDH is also available (Triage Panel). EIAs
can be subdivided in well-type EIAs (results are displayed as
a colour change which can be detected visually or photo-
spectrometically) and membrane-type EIAs (results can be
visually read from a membrane). The single-use membrane-
type EIAs are suitable for testing solitary samples; well-type
EIAs are suitable for testing samples in batches.
Real-time polymerase chain reaction (RT-PCR) is a nucleic
acid ampliﬁcation technique that can be used to detect the
presence of toxin genes directly from stools. Targeted genes
are the tcdB gene (regulating toxin B production) or the tcdC
gene (the putative negative regulator of toxin A and B pro-
duction). Base pair deletions in the tcdC gene, thought to be
responsible for toxin hyperproduction, can also be detected.
Eligibility criteria
Studies evaluating diagnostic tests for CDI were eligible for
inclusion. Studies had to: (i) describe original research; (ii)
compare the index test to a reference standard (CCA or
TC); (iii) be performed on clinical human stool samples; and
(iv) report sufﬁcient information to allow us to calculate sen-
sitivities and speciﬁcities. If assays to detect toxin and non-
toxin producing C. difﬁcle were evaluated (e.g. GDH tests),
culture without further characterization was also accepted as
a standard.
We excluded studies if: (i) the reference test was not per-
formed on all samples, but only on positive, negative or dis-
cordant samples (to exclude partial veriﬁcation bias); (ii) the
index test was partly used as a reference standard; (iii) the
reference standard included clinical data or was a composite
of more than one test; (iv) not all samples were tested by
the same reference test; or (v) in studies using CCA as a ref-
erence test, neutralization to determine the speciﬁcity of the
cytopathic effect was not executed.
Tests were included in the analysis only if they were still
available. They were categorized as well-type enzyme immuno-
assays (EIAs) for detection of toxins A and/or B, membrane-
type EIAs for detection of toxins A and/or B, well-type EIAs
for detection of glutamate dehydrogenase (GDH), membrane-
type EIAs for detection of GDH, and nucleic acid ampliﬁcation
techniques, such as Real-time PCR.
Search strategy
We searched Pubmed, EMBASE, Web of Science, CINAHL
and the Cochrane Library for studies concerning the labora-
tory diagnosis of C. difﬁcile infections. Searches were
performed with the support of a librarian, using the search
strategy displayed in Appendix S1. In addition, we checked
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the references of relevant studies for additional articles.
Searches were performed in July 2008 and in July 2009.
Meeting abstracts were excluded. Only articles published in
the English language were included.
Data review and outcome measures
Two independent investigators (M.J.T.C and A.G) assessed
the study eligibility in a two-step selection process. Inconsis-
tencies were resolved by consensus. Data were extracted
using a prespeciﬁed data extraction form, as shown in
Appendix S2.
Sensitivity and speciﬁcity of different tests for detection of
CDI were chosen as the principal measures of outcome. To
be able to calculate these test characteristics, we extracted
the number of true positives, true negatives, false positives
and false negatives for each test under investigation, thereby
comparing the index test to the reference standard.
We created a quality assessment tool (Appendix S3)
which included items based on the ‘quality assessment for
studies of diagnostic accuracy’ (QUADAS) tool [19] and
items concerning the execution of the reference standard.
Diagnostic odds ratios were not calculated [20]. We
extracted additional information including year of publication
and information about the study population, storage condi-
tions of stool samples, and execution of the reference stan-
dard. In cases of incomplete data, the original authors were
contacted if possible.
The levels of evidence and grades of recommendation
were determined using the criteria in Appendix S5, which is
the standard of the Dutch Institute for Healthcare Improve-
ment CBO in The Netherlands.
Statistical analysis
We analyzed the test characteristics of EIAs detecting toxins
A and/or B and RT-PCR in comparison with CCA and TC.
We analyzed the test characteristics of EIAs detecting GDH
both in comparison with both CCA and TC (considering
GDH as a screening test for toxigenic C. difﬁcile) as well as
in comparison with culture (C) only (considering GDH as an
alternative for culture). For all index tests, sensitivity, speci-
ﬁcity, and their conﬁdence intervals were calculated from
the data supplied in each study. Sensitivity and speciﬁcity
were pooled in a ﬁxed effects model. The proportions were
weighted according to the inverse of the squared standard
error. Only data from the initial test results were used,
unless data were presented after repeated testing (eight
studies). Intermediate results were not included in calcula-
tions of sensitivity and speciﬁcity. We calculated positive and
negative predictive values (PPVs and NPVs), using hypotheti-
cal CDI prevalences of 5%, 10%, 20% and 50% in the tested
population. We used the weighted mean of the NPVs and
PPVs by combining individual studies assessing a speciﬁc
index test. For data processing and statistical analysis, we
used REVIEW MANAGER 5.0 software (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008).
Results
Literature search
We identiﬁed 847 unique citations by search in Pubmed, EM-
BASE, Web of Science, CINAHL and the Cochrane Library.
One additional study was identiﬁed by an expert. A summary
of the selection process is shown in Fig. 1. We excluded 777
papers on the basis of title and abstract. Of the 71 poten-
tially relevant papers retrieved for more detailed assessment,
28 were excluded from further analysis: 15 studies investi-
gated tests that were no longer commercially available; three
studies did not test all samples with the reference test; three
studies used an inappropriate reference standard; two stud-
ies comprised non-clinical human stool samples; two studies
did not report sufﬁcient information to allow us to calculate
sensitivity and speciﬁcity; one study using CCA did not
report if neutralization of the cytopathic effect was executed;
and for two studies, full text articles were not available.
Therefore, a total of 43 studies was included in this system-
atic review [6–10,12–15,21–23,23–54].
Study characteristics
In total, 18 different diagnostic assays were investigated
(Table 1): 13 commercially available EIAs for detection of
toxins A and/or B (34 studies); four commercially available
EIAs for detection of GDH (14 studies); and one RT-PCR
(four studies). Details of the 43 included studies are summa-
rized in Table 2. The studies were published between 1991
848 potentially relevant
studies identified 
777 studies excluded
on the basis of title or abstract
71 studies selected 
for detailed assessment
28 articles excluded: 
15, tests no longer available
3, not all samples tested by reference
     method
2, wrong reference test 
1, reference test included clinical data
1, neutralization test was not performed
2, no clinical human stool samples
2, insufficient information
2, full-text article not available
43 studies included
in systematic review
FIG. 1. Summary of selection process.
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and 2008 and the number of included samples ranged from
56 to 1468. Cytotoxicity assay was the reference test of
choice in the majority of studies (85%).
Quality assessment
For each study, the items of the quality assessment form
were scored (Appendix S4).
In 22/43 studies, one or more selection criteria (consistency
of samples, age of patients, suspicion of CDI) were not
described. Twenty-ﬁve of 43 studies (58%) included unformed
stool samples only, none of 43 studies (21%) included both
unformed and formed stool samples, and nine studies (21%)
did not report the consistency of tested samples. Blinding of
investigators was reported in 12/43 studies. Intermediate test
results (i.e. not interpretable, difﬁcult to interpret, invalid or
weak positive results) were reported in 17/43 studies (40%),
including four membrane-type EIAs (six studies using the Tri-
age assay [13,14,30,31], the ColorPac Toxin A assay [31], and/
or the Immunocard C. difﬁcile assay [39,54]). Repeated testing
of samples with an initial intermediate result was performed in
nine studies. Of these, eight studies reported results only after
repeated testing [31,33,43–46,53,54] and one study reported
the results of both initial and repeated testing [48]. In one
study, samples with intermediate results after repeated testing
were called negative [53].
In 10/37 studies using CCA as the reference test, storage
conditions of the samples before testing with CCA were not
reported or insufﬁciently reported. In the remaining 27
studies, samples were refrigerated at 2–8C (16/26 studies),
frozen at )20 till )80C (8/26 studies) or partly refrigerated
and partly frozen (2/26 studies). All samples stored at 4C
were tested within 72 h. Studies in which (part of) the sam-
ples were frozen (6/10) reported that samples were thawed
only once; one study reported that samples were thawed no
more than twice. Commercial CCAs were used in 9/37
studies; in-house CCAs were used in 30/37 studies. The
most frequently used cell lines were Vero cells (12 studies),
MRC-5 cells (eight studies), and HFF cells (six studies).
Test performances
Calculated sensitivities and speciﬁcities of index tests are
presented in Tables 3A–C. Discrepancies between the pub-
lished data and the recalculated data were observed in
one study; the speciﬁcity was incorrectly calculated as con-
ﬁrmed by the original author [12]. In Fig. 3a, index tests
are compared with CCA as a reference standard. Sensitivi-
ties ranged from 0.31 to 0.99 for EIAs detecting toxins A
and/or B, from 0.80 to 0.97 for EIAs detecting GDH and
from 0.87 to 1.00 for RT-PCR. Speciﬁcities ranged from
0.65 to 1.00 for EIAs detecting toxins A and/or B, from
0.75 to 0.97 for EIAs detecting GDH, and from 0.94 to
1.00 for RT-PCR. No differences were observed among
studies in which samples were stored at 4C or frozen,
or in which storage conditions were not described (data
not shown). It is therefore tempting to speculate that
samples in these studies were appropriately stored. In
Fig. 3b, index tests are compared with toxigenic culture as
the reference standard. Sensitivities ranged from 0.32 to
0.79 for EIAs detecting toxins A and/or B. The sensitivity
of Immunocard C. difﬁcile was 0.60; the sensitivity of RT-
PCR was 0.86. Speciﬁcities ranged from 0.84 to 1.00 for
EIAs detecting toxin A and/or B. The speciﬁcity of Immu-
nocard C. difﬁcile was 0.76; the speciﬁcity of RT-PCR was
0.97. In Fig. 3c, GDH EIAs are compared with culture as a
reference standard. Sensitivities ranged from 0.71 to 1.00.
Speciﬁcities ranged from 0.67 to 0.99.
TABLE 1. Tests included in the
analysis
Type Test Target Manufacturer
A: well-type EIA toxins
A and/or B
Clostridium difﬁcile tox A/B II Toxins A and B Techlab
Premier tox A Toxin A Meridian
Premier tox A/B Toxins A and B Meridian
ProSpecT A/B Toxins A and B Remel
Ridascreen A/B Toxins A and B R-Biopharm
B: membrane-type EIA
toxins A/B
C. difﬁcile tox A test Toxin A Oxoid
Clearview tox A Toxin A Oxoid
ColorPac toxin A Toxin A Becton Dickinson
Immunocard tox A/B Toxins A and B Meridian
Immunocard tox A Toxin A Meridian
Triage tox A Toxin A Biosite
Tox A/B Quik Chek Toxins A and B Techlab
XpecT A/B Toxins A and B Remel
C: well-type ElAs GDH C. difﬁcile chek-60 GDH Techlab
D: membrane-type ElAs GDH Immunocard C. difﬁcile GDH Meridian
C. difﬁcile quik chek GDH Techlab
Triage GDH GDH Biosite
E: RT-PCR – tcdB or tcdC –
EIA, enzyme immunoassay; RT-PCR, real-time polymerase chain reaction.
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No important differences in test characteristics were
observed among studies that tested unformed samples only
or studies that tested both formed and unformed stool
samples.
Table 4 shows calculated mean sensitivities and speciﬁci-
ties for all types of index tests compared with CCA
(Table 4A), toxigenic culture (Table 4B), and culture
(Table 4C). Sensitivities ranged from 0.72 to 0.93 in
comparison with CCA, from 0.52 to 0.86 in comparison
with toxigenic culture, and from 0.88 to 0.89 in comparison
with culture. Speciﬁcities ranged from 0.89 to 0.98 in com-
parison with CCA, from 0.76 to 0.98 in comparison with
toxigenic culture, and from 0.91 to 0.97 in comparison with
culture.
TABLE 2. Characteristics of included studies
Author Year
Reference
test Index test(s)
Total no.
Samples Study population
Prev.
CDI (%)
Miendje
Deyi et al.
2008 CCA Immunocard tox A/B, XpecT CD toxin A/B,
CD toxin A test, Tox A/B Quik Chek
100 unformed stools suspected of CDI,
age >65 yrs
23
Sloan et al. 2008 TC Premier tox A/B, Xpect C. difﬁcile toxin A/B,
Immunocard A/B, Triage tox A, RT-PCR
200 unformed stools suspected of CDI 22
Fenner et al. 2008 C C. difﬁcile chek-60 1468 all stools suspected of CDI, adults 5
TC Tox A/B Quik Chek 172 all GDH-positive stools, adults 60
Reyes et al. 2007 C Triage GDH, C. difﬁcile quik chek 401 unformed stools suspected of CDI 17
Reller et al. 2007 C C. difﬁcile chek-60 439 stools suspect of CDI, all ages 26
Musher et al. 2007 CCA Premier tox A/B, Immunocard A/B 446 all stools suspected of CDI, adults 17
CCA C. difﬁcile tox A/B II, ProSpecT A/B 131 all stools suspected of CDI, adults 41
Van den
Berg et al.
2007 CCA Premier tox A/B, RT-PCR 540 unformed stools suspected of CDI, all
unformed stools after >72h
admission, adults
6
Ticehurst et al. 2006 CCA C. difﬁcile chek-60 266 stools suspected of CDI 9
Van den
Berg et al.
2006 CCA RT-PCR 85 all unformed stools after >72h
admission, adults
7
Van den
Berg et al.
2005 CCA Immunocard tox A/B 367 unformed stools suspected of CDI,
all unformed stools after >72h
admission, adults
6
Snell et al. 2004 C C. difﬁcile chek-60, Triage-GDH 497 unformed stools suspect of CDI 19
TC Triage-Tox A, C. difﬁcile tox A/B II
Zheng et al. 2004 C, CCA C. difﬁcile chek-60 992 all stools suspected of CDI, all ages 14
Anderson et al. 2003 CCA Clearview tox A 166 unformed stools suspected of CDI,
all unformed stools after >72h admission
8
Be´langer et al. 2003 CCA RT-PCR 56 unformed stools suspect of CDI 52
Turgeon et al. 2003 CCA Immunocard C. difﬁcile, Immunocard tox A,
Triage panel
1003 all stools suspected of CDI, all ages 10
Massey et al. 2003 CCA Triage panel, C. difﬁcile tox A/B II 557 unfomed stools suspected of CDI, adults 26
Alfa et al. 2002 CCA Triage panel 400 unfomed stools suspected of CDI 15
O’Connor et al. 2001 CCA Immunocard tox A, CD toxin A test,
C. difﬁcile tox A/B 11, Premier tox A/B
200 stools suspected of CDI, adults 31
Landry et al. 2001 CCA Triage panel 90 unfomed stools suspected of CDI, adults 18
Vanpoucke et al. 2001 CCA Ridascreen tox A/B, Clearview tox A,
Colorpac, Triage panel
156 unfomed stools suspected of CDI 32
Patel et al. 2001 CCA Clearview tox A, Immunocard tox A 537 unfomed stools suspected CDI, adults 9
Barbut et al. 2000 C Triage-GDH 304 unformed stools suspected of CDI, adults 25
CCA Triage panel
Fedorko et al. 1999 CCA, TC Immunocard tox A 654 all stools suspected of CDI 10
Fille et al. 1998 CCA CD toxin A test 105 all stools suspected of CDI, all ages 21
Bentley et al. 1998 CCA Clearview tox A 407 unformed stools suspected of CDI 29
Barbut et al. 1997 CCA, TC Immunocard tox A 236 stool suspected of CDI 14
Jacobs et al. 1996 TC, C Immunocard C. difﬁcile 150 unformed stools suspected of CDI, all ages 12
TC Premier tox A 258 unformed stools suspected of CDI, all ages 8
Staneck et al. 1996 CCA Immunocard C. difﬁcile 906 unclear 14
Siarakas et al. 1996 CCA Premier tox A 184 unformed stools suspected of CDI,
all unformed stools after >72h admission
20
Langley et al. 1995 CCA Premier tox A 200 unformed stools suspected of CDI 20
Arrow et al. 1994 CCA Premier tox A 160 unclear 33
Bowman et al. 1994 CCA Premier tox A 314 unclear 21
Merz et al. 1994 CCA Premier tox A 699 stools suspected of CDI 8
Altaie et al. 1994 CCA Premier tox A 410 unformed stools suspected of CDI,
age 2-28 yrs
19
Whittier et al. 1993 CCA Premier tox A 326 unformed stools suspected of CDI, all ages 10
Knapp et al. 1993 CCA Premier tox A 301 formed and unformed stools 16
Gilligan et al. 1993 CCA Premier tox A 559 stools suspected of CDI 6
Barbut et al. 1993 CCA, TC Premier tox A 284 stools suspected of CDI 18
Doern et al. 1992 CCA Premier tox A 315 stools suspected of CDI 22
DeGirolami 1992 CCA Premier tox A 496 stools suspected of CDI, all ages 16
Borriello et al. 1992 CCA Premier tox A 101 unformed stools suspected of CDI 68
Delme´e et al. 1992 CCA, TC Premier tox A 228 unformed stools suspected of CDI, all ages 29
DiPersio et al. 1991 CCA, TC Premier tox A 313 stools suspected of CDI 14
CCA, cell cytotoxicity assay; TC, toxigenic culture; C, culture; CDI, Clostridium difﬁcile infection; Prev., prevalence; RT-PCR, real-time polymerase chain reaction.
CMI Crobach et al. Recommendations for diagnosing CDI 1057
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1053–1066
Negative and positive predictive values
In Table 5, the calculated mean sensitivities, speciﬁcities, PPVs
and NPVs of the index tests are compared with reference
standards CCA (Table 5A), toxigenic culture (Table 5B) and
culture (Table 5C). PPVs ranged from 0.12 to 1.00 at a
prevalence of 5%. At a prevalence of 50%, PPVs ranged
from 0.71 to 1.00. NPVs ranged from 0.97 to 1.00 at a
prevalence of 5%. At a prevalence of 50%, NPVs ranged from
0.62 to 0.96.
Discussion
In the present systematic review, we evaluated the diagnostic
accuracy of various tests for the diagnosis of CDI. We
observed no important differences in sensitivities and speci-
ﬁcities between well-type or membrane-type EIAs, although
EIAs detecting toxins A and/or B tended to be less sensitive
than the other types of tests. When EIAs for detection of
TABLE 3A. Calculated sensitivities and speciﬁcities compared to cell cytotoxicity assay
Type Index test Study Sensitivity (95% CI) Speciﬁcity (95% CI)
Well-type EIA toxin A/B Clostridium difﬁcile tox A/B II Massey 2003 0.75 (0.67, 0.82) 0.98 (0.96, 0.99)
C. difﬁcile tox A/B II Musher 2007 0.96 (0.87, 1.00) 0.87 (0.77, 0.94)
Premier tox A Knapp 1993 0.65 (0.50, 0.78) 0.95 (0.92, 0.98)
Premier tox A Doern 1992 0.69 (0.56, 0.79) 1.00 (0.99, 1.00)
Premier tox A Borriello 1992 0.71 (0.59, 0.81) 1.00 (0.89, 1.00)
Premier tox A Siarakas 1996 0.72 (0.55, 0.86) 0.87 (0.81, 0.92)
Premier tox A Barbut 1993 0.73 (0.58, 0.84) 1.00 (0.98, 1.00)
Premier tox A Bowman 1994 0.78 (0.66, 0.87) 1.00 (0.98, 1.00)
Premier tox A DiPersio 1991 0.84 (0.70, 0.93) 0.99 (0.97, 1.00)
Premier tox A Whittier 1993 0.84 (0.67, 0.95) 0.97 (0.94, 0.99)
Premier tox A DeGirolami 1992 0.85 (0.75, 0.92) 0.98 (0.96, 0.99)
Premier tox A Arrow 1994 0.85 (0.72, 0.93) 0.99 (0.95, 1.00)
Premier tox A Langley 1995 0.87 (0.73, 0.96) 0.96 (0.92, 0.99)
Premier tox A Merz 1994 0.87 (0.75, 0.95) 0.98 (0.96, 0.99)
Premier tox A Delmee 1992 0.88 (0.77, 0.95) 0.96 (0.91, 0.99)
Premier tox A Gilligan 1993 0.89 (0.78, 0.96) 0.97 (0.95, 0.98)
Premier tox A Altaie 1994 0.93 (0.85, 0.98) 1.00 (0.99, 1.00)
Premier tox A/B O’Connor 2001 0.82 (0.70, 0.91) 0.99 (0.96, 1.00)
Premier tox A/B Van den Berg 2007 0.97 (0.83, 1.00) 0.94 (0.92, 0.96)
Premier tox A/B Musher 2007 0.99 (0.93, 1.00) 0.97 (0.95, 0.99)
ProSpecT A/B Musher 2007 0.91 (0.80, 0.97) 0.97 (0.91, 1.00)
Ridascreen A/B Vanpoucke 2001 0.57 (0.43, 0.70) 0.97 (0.92, 0.99)
Membrane-type EIA toxin A/B C. difﬁcile tox A test O’Connor 2001 0.49 (0.36, 0.62) 0.99 (0.96, 1.00)
C. difﬁcile tox A test Fills 1998 0.68 (0.45, 0.86) 0.84 (0.75, 0.91)
C. difﬁcile tox A test Miendje Deyi 2008 0.87 (0.66, 0.97) 0.99 (0.93, 1.00)
Clearview tox A Patel 2001 0.70 (0.55, 0.83) 0.99 (0.97, 1.00)
Clearview tox A Bentley 1998 0.83 (0.75, 0.89) 0.97 (0.94, 0.99)
Clearview tox A Anderson 2003 0.85 (0.55, 0.98) 0.65 (0.57, 0.73)
Clearview tox A Vanpoucke 2001 0.89 (0.78, 0.96) 0.83 (0.75, 0.90)
ColorPac toxin A Vanpoucke 2001 0.89 (0.78, 0.96) 0.89 (0.82, 0.94)
Immunocard tox A/B Van den Berg 2005 0.91 (0.72, 0.99) 0.97 (0.95, 0.99)
Immunocard tox A/B Miendje Deyi 2008 0.91 (0.72, 0.99) 1.00 (0.95, 1.00)
Immunocard tox A/B Musher 2007 0.96 (0.89, 0.99) 0.99 (0.97, 1.00)
Immunocard tox A O’Connnor 2001 0.52 (0.39, 0.65) 1.00 (0.97, 1.00)
Immunocard tox A Turgeon 2003 0.56 (0.46, 0.66) 1.00 (0.99, 1.00)
Immunocard tox A Fedorko 1999 0.58 (0.46, 0.70) 0.99 (0.97, 0.99)
Immunocard tox A Patel 2001 0.74 (0.60, 0.86) 0.99 (0.98, 1.00)
Immunocard tox A Barbut 1997 0.82 (0.65, 0.93) 1.00 (0.98, 1.00)
Triage tox A Landry 2001 0.31 (0.11, 0.59) 1.00 (0.95, 1.00)
Triage tox A Alfa 2002 0.53 (0.40, 0.67) 1.00 (0.99, 1.00)
Triage tox A Turgeon 2003 0.59 (0.49, 0.69) 1.00 (0.99, 1.00)
Triage tox A Massey 2003 0.70 (0.62, 0.77) 0.99 (0.98, 1.00)
Triage tox A Vanpoucke 2001 0.77 (0.64, 0.87) 0.97 (0.91, 0.99)
Triage tox A Barbut 2000 0.79 (0.62, 0.91) 1.00 (0.98, 1.00)
Tox A/B QuikChek Miendje Deyi 2008 0.96 (0.78, 1.00) 1.00 (0.95, 1.00)
Well-type EIA GDH XpecT A/B Miendje Deyi 2008 0.91 (0.72, 0.99) 1.00 (0.95, 1.00)
C. difﬁcile chek-60 Zheng 2004 0.93 (0.87, 0.96) 0.89 (0.87, 0.91)
C. difﬁcile chek-60 Ticehurst 2006 0.96 (0.79, 1.00) 0.90 (0.86, 0.94)
Membrane-type EIA GDH Immunocard C. difﬁcile Turgeon 2003 0.80 (0.71, 0.87) 0.92 (0.91, 0.94)
Immunocard C. difﬁcile Staneck 1996 0.84 (0.77, 0.90) 0.92 (0.90, 0.94)
Triage GDH Turgeon 2003 0.89 (0.81, 0.94) 0.90 (0.88, 0.92)
Triage GDH Alfa 2002 0.91 (0.81, 0.97) 0.89 (0.85, 0.92)
Triage GDH Vanpoucke 2001 0.93 (0.83, 0.98) 0.75 (0.65, 0.83)
Triage GDH Landry 2001 0.94 (0.70, 1.00) 0.82 (0.72, 0.90)
Triage GDH Barbut 2000 0.97 (0.85, 1.00) 0.86 (0.81, 0.90)
Triage GDH Massey 2003 0.97 (0.93, 0.99) 0.86 (0.83, 0.89)
Real-time PCR RT-PCR Van den Berg 2007 0.87 (0.70, 0.96) 0.96 (0.94, 0.98)
RT-PCR Belanger 2003 0.97 (0.82, 1.00) 1.00 (0.87, 1.00)
RT-PCR Van den Berg 2006 1.00 (0.54, 1.00) 0.94 (0.86, 0.98)
RT-PCR, real-time polymerase chain reaction.
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GDH were compared with tests for the presence of toxi-
genic C. difﬁcile, they were less speciﬁc than EIAs detecting
toxins A and/or B or real-time PCR; this can be explained by
the fact that EIAs for GDH also detect non-toxigenic strains
of C. difﬁcile. The speciﬁcity of EIA for the detection of GDH
increased when they were compared with culture including
non-toxigenic strains.
As sensitivity and speciﬁcity are test characteristics but do
not take into account the different prevalences in the tested
population, we used different hypothetical prevalences for
calculations of negative predictive values (NPVs) and positive
predictive values (PPVs). The prevalence of a disease, for
example the prevalence of CDI among tested patients, can
be seen as the prior probability that a tested patient
actually has the disease. After having obtained a test result,
knowledge of sensitivity and speciﬁcity, as well as prior prob-
ability, can be used to determine the posterior probability of
TABLE 3B. Calculated sensitivities and speciﬁcities for index tests compared with toxigenic culture
Type Index test Study Sensitivity (95% CI) Speciﬁcity (95% CI)
Well-type EIA toxin A/B Clostridium difﬁcile tox A/B II Snell 2004 0.60 (0.48, 0.72) 0.98 (0.96, 0.99)
Premier tox A Jacobs 1996 0.61 (0.36, 0.83) 0.98 (0.96, 1.00)
Premier tox A Barbut 1993 0.65 (0.51, 0.78) 0.99 (0.97, 1.00)
Premier tox A Gilligan 1993 0.71 (0.59, 0.81) 0.97 (0.94, 0.98)
Premier tox A Delmee 1992 0.72 (0.61, 0.81) 1.00 (0.97, 1.00)
Premier tox A DiPersio 1991 0.79 (0.64, 0.90) 0.98 (0.95, 0.99)
Premier tox A/B Sloan 2008 0.48 (0.32, 0.63) 0.98 (0.94, 1.00)
Membrane-type EIA toxin A/B Immunocard tox A Fedorko 1999 0.56 (0.45, 0.68) 0.99 (0.98, 1.00)
Immunocard tox A Barbut 1997 0.77 (0.60, 0.90) 1.00 (0.98, 1.00)
Immunocard tox A/B Sloan 2008 0.48 (0.32, 0.63) 0.99 (0.95, 1.00)
Tox A/B Quik Chek Fenner 2008 0.53 (0.43, 0.63) 0.97 (0.90, 1.00)
Triage tox A Sloan 2008 0.32 (0.19, 0.48) 1.00 (0.98, 1.00)
Triage tox A Snell 2004 0.49 (0.37, 0.61) 1.00 (0.99, 1.00)
XpecT A/B Sloan 2008 0.48 (0.32, 0.63) 0.84 (0.77, 0.89)
Well-type EIA GDH Immunocard C. difﬁcile Jacobs 1996 0.60 (0.32, 0.84) 0.76 (0.68, 0.83)
Real-time PCR RT-PCR Sloan 2008 0.86 (0.73, 0.95) 0.97 (0.94, 0.99)
RT-PCR, real-time polymerase chain reaction.
TABLE 3C. Calculated sensitivities and speciﬁcities for index tests compared with culture of Clostridium difﬁcile
Type Index test Study Sensitivity (95% CI) Speciﬁcity (95% CI)
Well-type EIA GDH C. difﬁcile chek-60 Zheng 2004 0.71 (0.63, 0.78) 0.88 (0.85, 0.90)
C. difﬁcile chek-60 Fenner 2008 0.93 (0.88, 0.97) 0.97 (0.95, 0.97)
C. difﬁcile chek-60 Snell 2004 0.94 (0.86, 0.98) 0.98 (0.96, 0.99)
C. difﬁcile chek-60 Reller 2007 1.00 (0.98, 1.00) 0.67 (0.61, 0.72)
Membrane-type EIA GDH C. difﬁcile quik chek Reyes 2007 0.93 (0.84, 0.98) 0.95 (0.92, 0.97)
Immunocard C. difﬁcile Jacobs 1996 0.75 (0.59, 0.87) 0.90 (0.83, 0.95)
Triage GDH Snell 2004 0.85 (0.76, 0.92) 0.99 (0.97, 1.00)
Triage GDH Barbut 2000 0.91 (0.82, 0.96) 0.99 (0.96, 1.00)
Triage GDH Reyes 2007 0.93 (0.83, 0.98) 0.98 (0.95, 0.99)
TABLE 4A. Mean sensitivities and speciﬁcities for the differ-
ent types of index tests compared with cytotoxicity assay
Type (no. studies)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
Well-type EIA toxin A/B (22) 0.82 (0.79, 0.84) 0.97 (0.97, 0.98)
Membrane-type EIA toxin A/B (24) 0.72 (0.69, 0.74) 0.98 (0.97, 0.98)
Well-type EIA GDH (2) 0.93 (0.88, 0.97) 0.89 (0.87, 0.91)
Membrane-type EIA GDH (8) 0.90 (0.87, 0.92) 0.90 (0.88, 0.90)
Real-time PCR (3) 0.92 (0.83, 0.97) 0.96 (0.94, 0.98)
TABLE 4B. Mean sensitivities and speciﬁcities for the differ-
ent types of index tests compared with toxigenic culture
Type (no. studies)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
Well-type EIA toxin A/B (7) 0.66 (0.61, 0.71) 0.98 (0.97, 0.99)
Membrane-type EIA toxin A/B (7) 0.52 (0.47, 0.57) 0.98 (0.97, 0.99)
Membrane-type EIA GDH (1) 0.60 (0.32, 0.83) 0.76 (0.68, 0.83)
Real-time PCR (1) 0.86 (0.73, 0.95) 0.97 (0.94, 0.99)
TABLE 4C. Mean sensitivities and speciﬁcities for the differ-
ent types of index tests compared with culture of Clostrid-
ium difﬁcile
Type (no. studies) Sensitivity (95% CI) Speciﬁcity (95% CI)
Well-type EIA GDH (4) 0.89 (0.86, 0.91) 0.91 (0.90, 0.92)
Membrane-type EIA GDH (5) 0.88 (0.84, 0.91) 0.97 (0.96, 0.98)
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a test result. The posterior probability of a positive test
result (PPV) is the probability that a person has the disease,
given the positive result. In a tested population with a low
prior probability for the disease, a positive test result will be
only a proof of the disease only if the test is free of false
positives (speciﬁcity of 100%). Otherwise the posterior prob-
ability (PPV) will be only 50%, even in the case of a high sen-
sitivity, as can be seen in Table 5. A low PPV is associated
with unnecessary treatment of non-infected patients. On the
other hand, the NPV indicates the proportion of true nega-
tives among patients with a negative test result. A low NPV
will mean that many cases are not detected. This will lead to
insufﬁcient treatment and spread of infection as isolation
measures may not be imposed. To overcome the problem of
a low PPV, we propose a two-step approach, with a second
test in case of a positive ﬁrst test (Figs 2 and 3). Laborato-
ries can choose to use a toxin test or an assay directed to a
bacterial gene or enzyme. We performed a calculation to
assess the effect of a two-step approach with the following
assumptions: a sample of 10 000 tested patients and a preva-
lence of 5%. Two tests were performed: (i) Triage GDH
(sensitivity 0.94, speciﬁcity 0.87); and (ii) in case of a positive
test, Premier Tox A/B was performed (sensitivity 0.92, speci-
ﬁcity 0.96). This would lead to true negative test results in
9451 patients, true positive test results in 432, false negative
results in 68, and false positive results in 49. In total, among
all tested 10 000 patients, the test result will be incorrect in
c. 1% of the population. While this is a low overall error
rate, the consequences for individual patients could be
severe. Notably, false positive diagnoses could result in a
patient without true CDI being managed alongside real cases,
potentially resulting in cross-infection.
Many laboratories have implemented EIAs detecting toxins
A and B, as stand-alone tests for the diagnosis of CDI [5].
We found that these EIAs were quite speciﬁc, but less sensi-
tive in detecting CDI. Only when the tests were performed
in a population with a CDI prevalence of 50%, PPVs would
be acceptable (ranging from 0.75 to 1.00) due to their high
speciﬁcity. However, in an endemic situation, the prevalence
of CDI is expected to range between 5% and 10%. Due to
this low prevalence of disease, PPVs of most of these tests
would be unacceptably low. Only the most speciﬁc tests
(XpecT A/B and Tox A/B Quik Chek) would have acceptable
PPVs at these low prevalences, but these tests have been
evaluated in one study each and more data are required
before the recommendation obtains a grade of 1. As EIAs
detecting GDH were less speciﬁc than most EIAs detecting
toxins A and/or B and RT-PCR, their PPVs would be even
lower, both in high-risk and endemic situations.
We conclude that all currently available types are not suit-
able as stand-alone tests to diagnose CDI in endemic popula-
tions because of their low PPVs at these prevalences. Since
the NPVs of the tests were very acceptable at low preva-
lences, these tests (i.e. EIAs detecting toxins A and/or B,
EIAs detecting GDH, and real-time PCR) can be used as
screening tests in an endemic situation, with the emphasis on
a negative test result. When a negative test result is
obtained, CDI can be very reliably excluded. However, when
a positive test result is obtained, a conﬁrmatory test must
be performed to recognize a truly positive sample. There
TABLE 5A. Calculated PPVs and NPVs for the index tests compared with cell culture cytotoxicity assay at prevalence rates of
5, 10, 20 and 50% in the tested population
Type Index test (no. studies) Sensitivity Speciﬁcity
Prevalence
5%
Prevalence
10%
Prevalence
20%
Prevalence
50%
PPV NPV PPV NPV PPV NPV PPV NPV
Well-type EIA toxin A/B Clostridium difﬁcile tox A/B II (2) 0.81 0.96 0.52 0.99 0.69 0.98 0.84 0.95 0.95 0.83
Premier tox A (15) 0.81 0.98 0.68 0.99 0.82 0.98 0.91 0.95 0.98 0.84
Premier tox A/B (3) 0.92 0.96 0.55 1.00 0.72 0.99 0.85 0.98 0.96 0.92
ProSpecT A/B (1) 0.91 0.97 0.61 1.00 0.77 0.99 0.88 0.98 0.97 0.92
Ridascreen C. difﬁcile tox A/B (1 ) 0.57 0.97 0.50 0.98 0.68 0.95 0.83 0.90 0.95 0.69
Membrane-type EIA toxin A/B C. difﬁcile tox A test (3) 0.61 0.95 0.39 0.98 0.58 0.96 0.75 0.91 0.92 0.71
Clearview tox A (4) 0.82 0.92 0.35 0.99 0.53 0.98 0.72 0.95 0.91 0.84
ColorPac toxin A(1) 0.89 0.89 0.30 0.99 0.47 0.99 0.67 0.97 0.89 0.89
Immunocard tox A/B (3) 0.94 0.98 0.71 1.00 0.84 0.99 0.92 0.98 0.98 0.94
Immunocard tox A (5) 0.61 0.99 0.76 0.98 0.87 0.96 0.94 0.91 0.98 0.72
Triage tox A (6) 0.65 0.99 0.77 0.98 0.88 0.96 0.94 0.92 0.98 0.74
Tox A/B Quik Chek(1) 0.96 1.00 1.00 1.00 1.00 1.00 1.00 0.99 1.00 0.96
XpecT A/B(1) 0.91 1.00 1.00 1.00 1.00 0.99 1.00 0.98 1.00 0.92
Well-type EIA GDH C. difﬁcile Chek-60 (2) 0.93 0.89 0.31 1.00 0.48 0.99 0.68 0.98 0.89 0.93
Membrane-type EIA GDH Immunocard C. difﬁcile (2) 0.83 0.92 0.35 0.99 0.54 0.98 0.72 0.96 0.91 0.84
Triage GDH (6) 0.94 0.87 0.28 1.00 0.45 0.99 0.64 0.98 0.88 0.94
Real-time PCR RT-PCR (3) 0.92 0.96 0.55 1.00 0.72 0.99 0.85 0.98 0.96 0.92
RT-PCR, real-time polymerase chain reaction.
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are two options to conﬁrm positive results. Firstly, all posi-
tive samples can be tested by a reference test. This approach
was described by Ticehurst and colleagues[15]. They applied
a two-step algorithm in which specimens were ﬁrst tested
for the presence of GDH antigen by an EIA and the positive
results were conﬁrmed by CCA. Because only GDH-positive
samples were tested by CCA, this approach resulted in a
reduced CCA workload (by 75–80%). Also, their laborato-
ries’ expenses were signiﬁcantly less than if CCA alone had
been performed on all samples of patients suspected of
having CDI. Gilligan demonstrated that this two-step algo-
rithm had an enhanced ability to detect C. difﬁcile toxin-posi-
tive specimens (by 40%) compared with the results of an EIA
detecting toxins A and B [16]. Secondly, all positive samples
can be retested with a rapid test. As the tested population
will now have a higher CDI prevalence, PPVs will be accept-
able, especially if the more speciﬁc EIAs detecting toxins A
and/or B or real-time PCR are used instead of EIAs detecting
GDH. However, due to the higher CDI prevalence, NPVs
will be less acceptable. Therefore, samples with an initial
positive test result, but a negative second test result, require
testing with a reference method as a third step. The group
of Hussain has described such a three-step algorithm in
which specimens were ﬁrst tested by an EIA detecting GDH
and, if positive, the specimens were tested with an EIA
detecting toxins A and/or B. The GDH-positive, but toxin-
negative, samples were further tested with CCA. With this
three-step approach, results of c. 85% of samples were avail-
able on the day specimens were received and the need for
CCA testing was even further reduced to 15% [12–14].
Fenner and colleagues have also applied this three-step
approach. In their laboratory, the results of c. 92% of sam-
ples were available within a turnaround time of 4 h; only 8%
of samples had to be tested by CCA [22].
The lack of conﬁdence in the tests for CDI detection has
motivated some clinicians to submit multiple samples per
patient [11]. The value of this repeated testing can also be
deduced from the above-mentioned NPVs. In an endemic sit-
uation, all the above-mentioned rapid tests have high NPVs.
Therefore, submission of multiple samples for testing by one
of these tests will not increase the rate of detection of CDI
in an endemic setting. This was also observed by Mohan
et al. and Drees et al. [55,56]. However, in an epidemic set-
ting, NPVs of these tests will be signiﬁcantly lower due to
the higher prevalence of disease. For that reason, repeated
testing of stools will be of value to detect additional cases in
TABLE 5B. Calculated PPVs and NPVs for the index tests compared with toxigenic culture at prevalence rates of 5, 10, 20
and 50% in the tested population
Type Index test (no. studies) Sensitivity Speciﬁcity
Prevalence
5%
Prevalence
10%
Prevalence
20%
Prevalence
50%
PPV NPV PPV NPV PPV NPV PPV NPV
Well-type El A toxin A/B Clostridium difﬁcile tox A/B 11(1) 0.60 0.98 0.61 0.98 0.77 0.96 0.88 0.91 0.97 0.71
Premier tox A (5) 0.71 0.98 0.65 0.98 0.80 0.97 0.90 0.93 0.97 0.77
Premier tox A/B (1) 0.48 0.98 0.56 0.97 0.73 0.94 0.86 0.88 0.96 0.65
Membrane-type EIA toxin A/B Immunocard tox A (2) 0.63 1.00 1.00 0.98 1.00 0.96 1.00 0.92 1.00 0.73
Immunocard A/B (1) 0.48 0.99 0.72 0.97 0.84 0.95 0.92 0.88 0.98 0.66
Tox A/B Quik Chek(1) 0.53 0.97 0.48 0.98 0.66 0.95 0.82 0.89 0.95 0.67
Triage tox A (2) 0.43 1.00 1.00 0.97 1.00 0.94 1.00 0.88 1.00 0.64
XpecT A/B(1) 0.48 0.84 0.14 0.97 0.25 0.94 0.43 0.87 0.75 0.62
Membrane-type EIA GDH Immunocard C. difﬁcile (1) 0.60 0.76 0.12 0.97 0.22 0.94 0.38 0.88 0.71 0.66
Real-time PCR RT-PCR(1) 0.86 0.97 0.60 0.99 0.76 0.98 0.88 0.97 0.97 0.87
RT-PCR, real-time polymerase chain reaction.
TABLE 5C. Calculated PPVs and NPVs for the index tests compared with culture at prevalence rates of 5, 10, 20 and 50% in
the tested population
Type Index test (no. studies) Sensitivity Speciﬁcity
Prevalence
5%
Prevalence
10%
Prevalence
20%
Prevalence
50%
PPV NPV PPV NPV PPV NPV PPV NPV
Well-type EIA GDH C. difﬁcile Chek-60 (4) 0.89 0.91 0.34 0.99 0.52 0.99 0.71 0.97 0.91 0.89
Membrane-type EIA GDH C. difﬁcile quik chek(1) 0.93 0.95 0.50 1.00 0.67 0.99 0.82 0.98 0.95 0.93
Immunocard C. difﬁcile (1) 0.75 0.90 0.28 0.99 0.45 0.97 0.65 0.94 0.88 0.78
Triage GDH (3) 0.89 0.98 0.70 0.99 0.83 0.99 0.92 0.97 0.98 0.90
RT-PCR, real-time polymerase chain reaction.
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an epidemic setting, as was demonstrated by Debast et al.
[57] One of the strengths of the two- or three-step algo-
rithms is the high NPV of the ﬁrst test on the basis of which
samples with a negative test result are considered negative.
If such an algorithm would be used in an epidemic situation,
the NPV of this ﬁrst test, would be lower and, therefore,
there would be a possibility of missing cases. Consequently,
multiple sample submission would also be of beneﬁt if an
algorithm is used in an epidemic setting, but not if it is used
in an endemic setting. It should be emphasized that multiple
sample testing will increase the likelihood of obtaining false-
positive results, notably when low speciﬁcity tests are used.
In practice this creates a real dilemma, as it is difﬁcult to
ignore a positive result even when accompanied by several
other negative results.
As NPVs of rapid tests for CDI are dependent on the
prevalence of disease in the tested population, one might
consider using a more stringent sample selection strategy to
increase the prevalence of CDI in the tested population.
Restricting CDI testing to unformed samples, as is usually
done, does not seem to cause the diagnosis of CDI to be
missed [58]. On the contrary, restricting CDI testing to
patients with characteristic risk factors may lead to missing
cases. It is known that routine CDI testing in patients with-
out a request for such testing, but with diarrhoea and hospi-
talization for at least 72 h, improved the rate of CDI
diagnosis [6]. Moreover, the recent emergence of new C. dif-
ﬁcile strains may result in a greater than before spread of the
bacterium in the community and an increase in CDI outside
 EIA to detect TcdA and TcdB  EIA to detect GDH, or 
Real-time PCR to TcdB  
+ - - +
EIA to detect GDH, or 
Real-time PCR to TcdB, or 
Cytotoxicity assays 
EIA to detect TcdA and TcdB, or   
Cytotoxicity assay 
+ +– –
No CDI.  
No CDI C. difficile toxins are not 
detectable in faeces but C.  
difficile is present; CDI 
can not be excluded     
 CDI  is 
diagnosed 
 CDI is 
diagnosed 
Toxin detection or bacterial detection 
High clinical 
suspicion: 
toxinogenic culture* 
*  a positive toxinogenic culture always indicates the presence of 
toxin-producing C. difficile and makes further testing unnecessary
FIG. 2. Algorithm to diagnose CDI
Prevalence of the CDI-infected population 5%
Tested population n = 10 000
No CD infection
n = 9500
CD infection
n = 500
Triage GDH test: Sensitivity 0.94. Specificity 0.87
CD infection
Positive test
n = 470
No CD infection
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No CD infection
Negative test
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CD infection
Negative test
n = 30
False
negative
True
negative
Premier Tox A/B test: Sensitivity 0.92. Specificity 0.96
CD infection
Negative test
n = 38
False
negative
CD infection
Positive test
n = 432
True positive
No CD infection
Positive test
n = 49
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Negative test
n = 1 186
True
negative
Total tested = 10 000
True negative = 9451 (94.5%)
True positive = 432 (4.3%)
False negative = 68 (0.7%)
False positive = 49 (0.5%)
FIG. 3. Application of two-step algorithm in a population of 1000 patients with a CDI prevalence 5%.
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known risk groups [59]. Community-acquired CDI has been
diagnosed in patients without predisposing factors [60,61].
For 3 months in 2007–2008, three laboratories in The Neth-
erlands tested all unformed stool samples for C. difﬁcile sub-
mitted by general practitioners (GPs), irrespective of
whether GPs speciﬁcally requested this [60]. Of 2423
patients, 37 patients (1.5%) were positive. Age varied from 1
to 92 years and 18% were under age 20. Of 31 CDI patients,
20 (65%) had not been admitted to a healthcare institution
in the year before, 13 (42%) had not used antibiotics during
the prior 6 months, and eight (26%) had neither risk factor.
This is similar to the results of Wilcox et al. [61] who found
the proportion of positive samples to be 2.1% and the
absence of speciﬁc risk factors to be 25%. Since it appears
that CA-CDI is not a syndrome associated with speciﬁc
patient characteristics, we recommend testing for CDI in
patients with potential infective diarrhoea and with negative
tests for common enteropathogens, irrespective of age, prior
antibiotic use, comorbidity, co-medication, and onset of diar-
rhoea (community-acquired or nosocomial).
We suggest that CDI testing should be performed using
unformed stool samples of all patients with infectious
diarrhoeae who have been negative tests for common ente-
ropathogens. Secondly, all patients with diarrhoea who have
been hospitalized more than 72 h should be tested for CDI,
irrespective of the physicians’ request.
In the present systematic review, we analyzed the compar-
ison of index tests with the two reference tests for toxigenic
C. difﬁcile (i.e. CCA and TC) separately. Many controversies
exist concerning these two reference tests. CCA was the
ﬁrst test described [3] and is still the most widely used ref-
erence test, but it has many drawbacks. Besides being techni-
cally demanding and time-consuming, it is prone to altered
results due to toxin degradation during transport or storage
of the sample. It has been reported that storage at 4C dur-
ing 56 days had no discernible effect on C. difﬁcile toxins, but
that multiple cycles of freezing and thawing during this time
period may adversely affect toxin titres [62]. Toxigenic
culture is time-consuming but suffers less from inadequate
storage or transport conditions as in vitro toxin production is
measured. Because of this, it is reported as a more sensitive
test [4], but the clinical relevance of in vitro toxin production
is not entirely clear. Based on our results, we conclude that
toxigenic culture was indeed a more sensitive reference stan-
dard, as calculated sensitivities of index tests compared with
toxigenic culture were somewhat lower than compared with
CCA. In addition to being more sensitive and being affected
less by storage and transport, toxigenic culture also allows
the recovery of C. difﬁcile isolates which can be used for
molecular typing and susceptibility testing. Toxigenic culture
could be replaced by molecular tests, provided that the sen-
sitivity of these assays is comparable with culture.
None of the currently available tests is suitable as a stand-
alone test in endemic populations to diagnose CDI because of
their low PPVs at these prevalences. This conclusion is similar
to that drawn recently from a systematic review on diagnosis
of C. difﬁcile infection using toxin detection kits, but our analy-
sis differed on a few points [63]. Firstly, we excluded meeting
abstracts in our analysis since these are in general not peer-
reviewed. Secondly, we recalculated the NPV and PPV from
the rough data in the manuscript. Thirdly, Planche et al. com-
bined studies irrespective of the reference method used. We
analyzed studies using toxigenic culture or cell cytotoxicity
assay separately, since toxigenic culture is considered to be a
more sensitive method to detect C. difﬁcile. We acknowledge,
however, that the clinical signiﬁcance of detection of a toxi-
genic strain, but not free toxin, remains debatable. Finally, in
the review by Planche et al., no distinction was made between
well-type EIAs and the membrane-type EIAs. We analysed
these groups separately, since the implementation of these
tests in daily practice is very different.
In summary, if use of a reference standard test is not con-
sidered practical (e.g. because of access to cytotoxin testing
and/or culture) we recommend a two-step approach to
increase the PPV. The NPV is more difﬁcult to alter. As can
be seen from Fig. 3, using a two-test approach will lead to
68 false negative subjects (0.7%) among 10 000 tested. Fur-
ther reducing the number of false negative results would
require either re-testing of all subjects with a negative ﬁrst
test, or re-testing all subjects with a negative second test,
after an initially positive test. The ﬁrst scenario would
require retesting a total of 8,295 subjects, which is 83% of
the tested population. Assuming a sensitivity of a third test
of 0.92, in this scenario the 30 false negative results from
the ﬁrst test would be reduced to only two. The second
scenario would require a re-test in 1224 subjects and would
reduce the 38 false negative results after the second test to
35, again assuming a sensitivity of 0.92. These improvements
are, however, not signiﬁcant.
Further studies to validate the applicability of two-step
testing, including assessment of clinical features with patient
follow up, are required. We note that two-step testing will
increase the time needed to achieve a conﬁrmed positive
result. This emphasizes the need to manage patients with sus-
pected CDI on clinical grounds, notably isolating these individ-
uals as soon as is practicable in order to limit the
dissemination of C. difﬁcile in the hospital setting. A two-step
testing approach to CDI diagnosis will generate discrepant
results. This underscores the value of access to reference
tests, and the need for improved diagnostic methods in gen-
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eral, preferably molecular tests that can replace toxigenic cul-
ture.
Recommendations
Sample selection
• CDI testing should only be performed on unformed
stools (level 3).
CDI testing should be performed on unformed stool sam-
ples of all patients with potential infective diarrhoea and neg-
ative tests for common enteropathogens, irrespective of age,
prior antibiotic use, co-morbidity, co-medication, and onset
of diarrhoea (community-acquired or nosocomial) (level 3).
All patients with diarrhoea who have been hospitalized
more than 72 h should be tested for CDI, irrespective of the
physicians’ request (level 3). This does not mean that CDI
testing should not also be performed on samples submitted
within the ﬁrst 72 h of hospitalization
Patients with diarrhoeae who have been admitted in a
health-care facility within a period of 3 months prior to the
development of diarrhoea should also be tested for CDI.
CDI testing in an endemic setting and epidemic setting
• The diagnosis of C. difﬁcile infection should be based on
clinical signs and symptoms in combination with laboratory
tests.
The interpretation of C. difﬁcile laboratory results should
be done in the clinical context, taking into account the back-
ground prevalence of C. difﬁcile in the institution.
We recommend testing patients with a two-step protocol.
In the ﬁrst step, faeces samples could be investigated with an
EIA detecting GDH, an EIA detecting toxins A and B, or
molecular test detecting TcdB. Samples with a negative test
result can be reported as negative. Faeces samples with a
positive ﬁrst test result should be re-tested with a method
to detect free faeces toxins, or with a method to detect
GDH or toxin genes, dependent on the assay applied as ﬁrst
screening test (level1).
If free faeces toxins are absent but C. difﬁcle, TcdB or
GDH is present, CDI cannot be differentiated from asymp-
tomatic colonization.
Repeated sample submission during the same episode is
not recommended in an endemic situation (level 2), but may
be useful in an epidemic situation (level 3).
Performances of CDI tests
• According to data published to date, the test perfor-
mances of well-type assays and membrane-type assays to
detect toxins A and B of C. difﬁcile do not differ signiﬁcantly
when compared with cytotoxicity as a reference standard
(level 1).
Using toxigenic culture as a reference standard, all ana-
lysed assays had an unacceptable low sensitivity, with the
exception of molecular tests (level 1).
Well-type assays and membrane-type assays with GDH as
a target perform equally well and have an good correlation
with faeces culture of C. difﬁcile (level 1).
Using cell cytotoxicity assay as a reference standard and a
prevalence of CDI between 5% and 10%, the best PPV values
were observed with Tox A/B Quick Chek and Xpect A/B,
but only one study of each was included. The PPVs of the
tests decreased to unacceptably low rates when the toxi-
genic culture was used as reference standard (level 2).
The overall best performances were observed for Immu-
nocard toxA/B using cytotoxicity or toxigenic culture as
reference standard (Level 1) but only three studies have
been performed.
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